References
- Van den Eynden GG, Majeed AW, Illemann M, et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 2013;73:2031–43
- Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37
- Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol 2013;139:645–52
- Dittmar Y, Altendorf-Hofmann A, Schule S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol 2013;139:1317–25
- Selzner M, Morse MA, Vredenburgh JJ, et al. Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000;127:383–9
- Zinser JW, Hortobagyi GN, Buzdar AU, et al. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987;5:773–82
- Akinc A, Goldberg M, Qin J, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009;17:872–9
- Kim SI, Shin D, Choi TH, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A–I. Mol Ther 2007;15:1145–52
- Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347–51
- Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709–17
- Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173–8
- Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177–82
- Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25:1149–57
- Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111–14
- de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008;19:125–32
- Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release 2008;126:77–84
- Yano J, Hirabayashi K, Nakagawa S, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721–6
- Abedini F, Ismail M, Hosseinkhani H, et al. Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manage Res 2011;3:301–9
- Eliyahu H, Servel N, Domb AJ, Barenholz Y. Lipoplex-induced hemagglutination: potential involvement in intravenous gene delivery. Gene Ther 2002;9:850–8
- Simberg D, Weisman S, Talmon Y, et al. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem 2003;278:39858–65
- Kurosaki T, Kitahara T, Fumoto S, et al. Chondroitin sulfate capsule system for efficient and secure gene delivery. J Pharm Pharm Sci 2010;13:351–61
- Hattori Y, Nakamura A, Arai S, et al. In vivo siRNA delivery system for targeting to the liver by poly-l-glutamic acid-coated lipoplex. Res Pharma Sci 2014;4:1–7
- Kurosaki T, Kitahara T, Kawakami S, et al. Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release 2010;142:404–10
- Hattori Y, Arai S, Okamoto R, et al. Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver. Int J Pharm 2014;476:289–98
- Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008;68:9788–98
- Kato M, Hattori Y, Kubo M, Maitani Y. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm 2012;423:428–34
- Loisel S, Le Gall C, Doucet L, et al. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001;12:685–96
- Santel A, Aleku M, Roder N, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 2010;16:5469–80
- Unsal-Kacmaz K, Ragunathan S, Rosfjord E, et al. The interaction of PKN3 with RhoC promotes malignant growth. Mol Oncol 2012;6:284–98
- Zhang JS, Liu F, Conwell CC, et al. Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther 2006;13:429–37
- Tan Y, Liu F, Li Z, et al. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Mol Ther 2001;3:673–82
- Wada S, Obika S, Shibata MA, et al. Development of a 2′,4′-BNA/LNA-based siRNA for dyslipidemia and assessment of the effects of its chemical modifications in vivo. Mol Ther Nucleic Acids 2012;1:e45
- Henrotin Y, Mathy M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis 2010;2:335–48
- Tan GK, Tabata Y. Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-kappaB nuclear translocation. Acta Biomater 2014;10:2684–92
- Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol 2006;34:455–65
- Aichele P, Zinke J, Grode L, et al. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol 2003;171:1148–55
- Kurosaki T, Kodama Y, Muro T, et al. Secure splenic delivery of plasmid DNA and its application to DNA vaccine. Biol Pharm Bull 2013;36:1800–6
- Sutherland MD, Thorkildson P, Parks SD, Kozel TR. In vivo fate and distribution of poly-gamma-d-glutamic acid, the capsular antigen from Bacillus anthracis. Infect Immun 2008;76:899–906
- Leenders F, Mopert K, Schmiedeknecht A, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 2004;23:3303–13